logo

For the Inventor, By the Inventor

Tucson, AZ, United States of America

Anil Nair

This inventor holds 11 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignees: Aventis Pharma S.a., University of Missouri, Sanofi-Aventis. Active years: 2006-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Anil Nair. Retrieved from https://idiyas.com/inventor/anil-nair

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 11 

% Patents Active = 18.2

 

Average Co-Inventor Count = 5.2

ph-index = 3

Forward Citations = 35(Granted Patents)


Location History:

  • Oro Valley, AZ (US) (2007 - 2010)
  • Tucson, AZ (US) (2008 - 2012)
  • Tuscon, AZ (US) (2006 - 2013)

Company Filing History:

goldMedal4 out of 377 
 
Aventis Pharma S.a.
 patents
silverMedal4 out of 899 
 
University of Missouri
 patents
bronzeMedal2 out of 390 
 
Sanofi-Aventis
 patents
4. 1 out of 1,547 
 
Sanofi
 patents

Years Active: 2006-2013

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 8420824 - Substituted pyrazoles, compositions containing these, method of production and use (2013-04-16),
2. 8410286 - Substituted pyrazoles, compositions containing these, method of production and use (2013-04-02),
3. 8163768 - 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them (2012-04-24),
4. 8058290 - 7-substituted aza-indazoles, compositions containing same, production method and use thereof (2011-11-15),
5. 7989439 - Substituted pyrazoles, compositions containing these, method of production and use (2011-08-02),
6. 7825115 - Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2010-11-02),
7. 7776898 - Opioid receptor active compounds (2010-08-17),
8. 7354933 - Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors (2008-04-08),
9. 7294720 - Opioid receptor active compounds (2007-11-13),
10. 7164021 - Opiate analogs selective for the δ-opioid receptor (2007-01-16),
11. 7045520 - Opioid receptor active compounds (2006-05-16),

Title: Anil Nair: Innovator in Pharmaceutical Chemistry

Introduction

Anil Nair is a prominent inventor based in Tucson, AZ, known for his significant contributions to pharmaceutical chemistry. With a total of 11 patents to his name, he has made remarkable advancements in the field of drug development.

Latest Patents

Among his latest patents, Anil Nair has developed substituted pyrazoles, along with compositions containing these compounds. His work includes methods of production and use, particularly focusing on a compound of formula (I) and its salts. The disclosure details the specific components, including Ar, L, A, X, R, R, R, Ra, Rb, and Rare, as defined in the documentation. These compounds and their compositions are particularly relevant for use as drugs, showcasing Nair's innovative approach to pharmaceutical applications.

Career Highlights

Anil Nair has had a distinguished career, working with notable organizations such as Aventis Pharma S.A. and the University of Missouri. His experience in these institutions has allowed him to refine his expertise in drug formulation and development.

Collaborations

Throughout his career, Anil has collaborated with esteemed colleagues, including Marcel Patek and Jacques Mauger. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Anil Nair's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a leading inventor in the field. His work continues to impact drug development and improve therapeutic options.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…